Microsoft word - 120607_webinar_nursing law.doc
Nursing Law Update 2007
This program will cover recent Joint Commission and CMS changes and the legal implications. The
Adverse No Pay Events will also be addressed.
CEOs, COOs, CNOs, Nursing Leadership, Professional Staff Nurses, Pharmacists, ED Managers,
Joint Commission Coordinators, Risk Managers, PI Directors, Quality Improvement Coordinators, Compliance Officers,
and Patient Safety Officers and Staff. Date:
December 6, 2007 Time:
Sue Dill Calloway
has been a nurse attorney and medical-legal
consultant for more than 25 years. She has presented numerous
educational programs for nurses, physicians, and other health care
professionals on topics such as patient safety, The Joint Commission,
CMS, and HIPAA issues. Currently, Sue is the Director of Hospital Risk Management with the OHIC Insurance Company.
• CMS new security of medication standard
• CMS new restraint and seclusion regulations
• Death reporting of patients in restraints
• Joint Commission medication management tracer
• Medication errors as common cause of liability
• Skin assessment and POA documentation
• TJC new disruptive behavior standard
At the completion of this program, the participant will be able to:
1. Discuss hot topics in nursing practice including the new changes to the Joint Commission National Patient Safety
2. Discuss the new CMS 8 adverse events that Medicare will not pay.
3. Explain the new guidelines for donation after cardiac death.
4. Describe the new CMS regulations for reporting deaths of patients in restraints.
There is a site fee of $100 for IHA member hospitals for this course; $200 for all others. Advance
registration is required to ensure delivery of instructional materials. Registration Deadline: November 29, 2007.
Nursing Law Update 2007
City, State, Zip:__________________________________________________________________________________
IHA Member Hospital…………………………………$100
Non-IHA Member Hospital………………………….$200
Payment must be received in order to get program materials.
Registration deadline: November 29, 2007
___ Check (payable to IHA)
Name of Cardholder:___________________________________________________________________________ Card Number:________________________________________ Exp. Date:_______________________________ Amount $ _____________________________
Mail with your remittance to:
Boise, ID 83701-1278
Have questions or need more information?
Contact Toni Pugmire at (208) 338-5100 x201 [email protected]
ZEGERID OTC™ PROVIDES GREATER AND FASTER ACID CONTROL THAN PREVACID® 24HR ACCORDING TO HEAD-TO-HEAD CLINICAL STUDY -- Greater and More Rapid Acid Reduction Achieved at Full Effect as Measured on Day 7 -- WHITEHOUSE STATION, NJ, May 4, 2010 – Merck Consumer Care today announced results of a head-to-head clinical study showing that ZEGERID OTC™ offers greater and faster ac
Mersey ADR Newsletter Issue 22 Autumn 2003 In this issue: Serious reactions generally… ▼ Fluoroquinolones and tendon disorders ▼ Serious reactions generally… Adverse drug reactions (ADRs) are a major problem, both in ▼ …and serious reactions with NSAIDs hospital and in the community. However, it is estimated that only about 10% of serious